American Society for Bone and Mineral Research

Incidence rates of hypocalcemia in women with postmenopausal osteoporosis are comparable between those treated with denosumab or bisphosphonate monotherapy and the rate of hypocalcemia among those treated with denosumab is consistent with the labeled risk, study data show.

The risks for new vertebral, clinical and nonvertebral fractures were reduced and bone mineral density increased in postmenopausal women assigned romosozumab followed by denosumab, according to results from the FRAME extension study presented at the American Society for Bone and Mineral Research Annual Meeting.

Adults with type 2 diabetes and obesity are at increased risk for any fracture, major osteoporotic fractures and hip fractures with longer duration of diabetes and higher HbA1c levels vs. those with shorter duration and lower levels, study data show.

Bone mineral density-associated genetic variants may predict lifetime fracture risk for men and women, study data show.

Postmenopausal women treated with abaloparatide for 18 months followed by 2 years of alendronate therapy saw a significant reduction in both vertebral and nonvertebral fractures through 3.5 years compared with patients assigned placebo followed by alendronate, according to findings from the ACTIVExtend study.

Women diagnosed with osteoporosis who use osteoporosis medications persistently for at least 60 days have a lower risk for fracture compared with women who do not use their medications persistently, study data show.

Postmenopausal women with low bone mineral density assigned denosumab therapy had less deterioration of trabecular microstructure at the distal tibia compared with women assigned placebo, study findings show.